medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2009, Number 11

<< Back

Ginecol Obstet Mex 2009; 77 (11)

Clinical Practice Guidelines 2008. Mexican College of Obstetrics and Gynecology Specialists. Diagnosis and treatment of idiopathic overactive bladder

Velázquez SMP, Solano SSR, López MNA, Rodríguez CS

Language: Spanish
References: 130
Page: 331-370
PDF size: 762.28 Kb.


Text Extraction

No abstract


REFERENCES

  1. Epidemiología

  3. Abrams P The standardization of terminology of lower urinary tract lunction: Report from the standardization sub-commitee of the international continence society. Neurourol Urodyn 2002;21: 167-78.

  4. Miller J, Hoffman E. The causes and consequences of overactive bladder. J Womens Health (farchmt). 2006;15:251-60.

  5. Miller JJ, Sand PK. Diagnosis and treatment of overactive bladder: Minerva Ginecol. 2005;57:501-20.

  6. Currie CJ, McEwan P, Poole CD, Odeyemi lA, Datta SN. Morgan Cl. The impact of the overactive bladder on health-related utility and quality of life. BJU Int. 2006; 97:1267-72.

  7. Patel AS, O’Leary ML, Stein RJ, Leng W W, Chancellor MB, Patel SG, Borello-France D. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006;32:77-87.

  8. Solano-Sánchez SR, Velásquez MP, Rodríguez S, Kunhardt J. Estudio comparativo de la prevalencia de vejiga hiperactiva en pacientes menores de 50 años con y sin hiperprolactinemia. Ginecol Obstet Méx 2006;74:345-8.

  11. Fisiopatología

  13. Miller J, Hoffman E. The causes and consequences of overactive bladder. J Womens Health (Larchmt). 2006; 15:251-60.

  14. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862-7.

  15. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175:1773-6.

  16. Maake C, Landman M, Wang X, Schmid DM, Ziegler U, John H. Expression of smoothelin in the normal and the overactive human bladder. J Urol. 2006;175(3 Pt 1):1152-7.

  17. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of Cfliber bladder afferent activity in rats. J Urol 2005;174:2032-6.

  18. Solano-Sánchez SR, Velásquez MP, Rodríguez S, Kunhardt J. Estudio comparativo de la prevalencia de vejiga hiperactiva en pacientes menores de 50 años con y sin hiperprolactinemia. Ginecol Obstet Méx 2006;74:345-348.

  19. Solano-Sánchez SR. Prolactin plasma levels in women with and without idiophatic overactive bladder. Intern Urogynecol J 2007;18 (suppl. 1):S74

  22. Etiología y factores de riesgo

  24. Riccetto C, Palma P, Tarazona A. Aplicaciones clínicas de la teoría integral de la continencia. Actas Urol Esp 2005;29:31-40.

  25. Pinna C, Sanvito P, Puglisi L. Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor From rat with outlet obstruction. Lile Sci. 2006;79:1301-6.

  26. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology. 2002;60(SuppI 1):50-5.

  27. Fitzgerald MP, et al. Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol. 2006; 175(3 Pt 1):989-93.

  28. Bidmead J. and Cardozo L. Retropubic Urethropexy (Burch Colposuspension). Int Urogynecol J 2001;12:262-5.

  29. Segal JL, Vassallo B, Kleeman S, Silva WA, Karram MM. Prevalence of persistent and de novo overactive bladder symptoms alter the tension-free vaginal tape. Obstet Gynecol. 2004; 104:1263-9.

  30. Jost WH. Autonomic dysregulations in Parkinson’s syndrome. Schweiz Rundsch Med Prax. 2005;94:1639-46.

  31. Sakakibara R, et al. Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer’s disease. Neurourol Urodyn. 2005;24:273-5.

  32. Bunyavejchevin S. Risk lactors of lemale urinary incontinence and overactive bladder in Thai postmenopausal women. J Med Assoc Thai. 2005; 88 Suppl 4: S119-23.

  33. Teleman PM, et al. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. BJOG. 2004;1(11):600-4.

  34. Dallosso HM. Nutrient composition of the diet and the development of overactive bladder: a longitudinal study in women. Neurourol Urodyn. 2004;23:204-10.

  36. Consideraciones clínicas

  38. MacDiarmid S, Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opino 2005;21:1413-21.

  39. Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL. Nocturnal polyuria in women with overactive bladder symptoms and nocturia. Am J Obstet Gynecol. 2005;192:1682-6.

  40. Homma Y, et al. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005;96:1314-8.

  41. Irwin DE, Milsom i, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:’96-100.

  42. Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005; 47:439-46.

  43. Patel AS, et al. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006;32:77-87.

  44. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology. 2005;65:1109-12.

  46. Diagnóstico

  48. Nygaard i, Heit M. Stress Urinary Incontinence. Obstet GynecoI 2004;104:607-20.

  49. Staskin DR, Wein AJ, Andersson KE, Bauer SB, Blaivas JG, Burgio KL, Cardozo L et al Overview consensus statement. Urology 2002; 60 (Supp 5A): 1-6.

  50. Coyne KS, Margolis MK, Zyczynski T, Elinoff V, Roberts R. Validation of an OAB screener in a primary care patient population in the US. Poster presented at the Annual Meeting of the International Continence Society; August 23-27,2004; Paris, France.

  51. Abrams P, Avery K, Zyczynki T, Kopp Z, Coyne K. Valoración de las respuestas del paciente en la vh: cuestionarios VH-Q, VH-Q SF, herramienta para diagnosticar la VH y CCI-VH.

  52. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther. 2005;22:381-94.

  53. Miller JJ, Sand PK. Diagnosis and treatment of overactive bladder. Minerva Ginecol. 2005;57:501-20.

  54. Abrams P. The standardization of terminology of lower urinary tract lunction: Report from the standardization sub-committee of the international continence society. Neurourol Urodyn 2002;21:167-78.

  55. Blaivas JG, Groutz A, et al. Does the method of cystometry affect the incidence of involuntary detrusor contraction? A prospective randomized urodynamic study. Neurourol Urodyn 2001; 20:141-6.

  56. Primer consenso Venezolano en Vejiga Hiperactiva. Sociedad Venezolana de Urología y Sociedad de Obstetricia y Ginecología de Venezuela. Caracas 2005.

  58. Tratamiento

  60. David A, Ginsberg MD. Evaluation and Treatment of Overactive Bladder. FACS. Urology. Medscape.com. August 2006.

  61. Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991 ;265:609-13.

  62. Fantl JA, Behavioral intervention for community-dwelling individuals with urinary incontinence. Urology. 1998; 51 (suppl 2a):30-4.

  63. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications lor overactive bladder syndrome in adults (Cochrane Review). In: The Cochrane Library, Issue 4, 2007. Oxford: Update Software. http://www.medscape.com/viewprogram/4499.

  64. Andersson KE, Appell R, Cardozo L, et al. 3rd International Consultation on Incontinence. Pharmacological treatment 01 urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Volume 2. Plymouth, UK: Health Publication Ltd, 2005;809-55.

  65. Chapple C, Khullar V, Gabriel Z, Dooley JA, The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5-26.

  66. Nitti VW/, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z; 037 Study Group. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. 2006;97:1262-6.

  67. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z; 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67:731-6; discussion 736.

  68. Rudy O, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275-80.

  69. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysls. Curr Med Res Opino. 2006;22:41-8.

  70. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22: 1 013-28.

  71. Wagg A, Wyndaele JJ, Sieber P, Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4:14-24.

  72. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training. biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management ot overactive bladder. Urology. 2004;63:61-6.

  73. Wagg Adrian et al. Current and future trends in the management of overactive bladder. International Urogynecology Journal 2006.

  74. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No. CD005429. D0I: 10.1002/14651858.CD005429.

  75. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006. Issue 4. Art. No. CD003193. DOI 10.1002/14651858.CD003193.pub3

  76. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No. CD003190. DOI: 10.1002/14651858.CD003190.pub4.

  77. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No. CD001308. DOI10.1002/14651858.CD001308.pub2

  78. Cardozo L, Lisec M, Millard R, van Vierssenrip O, Kuzmin I, Drogendijk et. al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patientes with overactive bladder. J Urol 2004; 172:1919-24.

  79. Waetjen E, Dwyer P. Estrogen therapy and urinary incontinence: what is the evidence and what do we tell our patients? Int Urogynecol J 2006; 17:541-5.

  80. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. (Cochrane Review). In: Cochrane Database of Systematic Reviews, Issue 2,2003. Oxford: Update Software.

  81. Cardozo L, Lose G, McClish D, et al A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstetricia et Gynecologica Scandinavica 2004; 83(10):892-7.

  82. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a metaanalysis. First report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynecology 1994; 83(1):12-8.

  83. Al Badr A, Ross S, Soroka D, et al. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? Journal of Obstetrics and Gynaecology Canada: JOGC 2003; 25(7):567-74.

  84. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004; 11 (1):49-56.

  85. Fantl JA, Bump RC, Robinson D, et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol 1996;88(5):745-9.

  86. Jackson S, Shepherd A, Brookes S, et al. The effect of oestrogen supplementation on postmenopausal urinary stress incontinence: a double-blind placebo-controlled trial. Br J Obstet Gynaecol 1999; 106(7):711-8.

  87. Wilson PD, Faragher B, Butler B, et al. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987; 94(6):568-74.

  88. Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993;18(1): 47-53.

  89. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000; 107 (8): 1 029-34.

  90. Ouslander JG, Greendale GA, Uman G, et al. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. Journal of the American Geriatrics Society 2001; 49(6):803-7.

  91. Rufford J, Hextall A. Cardozo L, et al. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. International Urogynecology Journal 2003; 14(2):78-83.

  92. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. International Journal of Gynecology and Obstetrics 2003; 82(2):187-97.

  93. Walter S, Wolf H, Barlebo H. et al. Urinary incontinence in postmenopausal women treated with oestrogens. Urologia Internationalis 1978; 33: 135-43.

  94. Samsioe G, Jansson I, Mellstrom D, et al. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas 1985; 7(4):335-42.

  95. Molander U, Milsom I, Ekelund P, et al. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the postmenopause. Maturitas 1990; 12(2): 113-20.

  96. Eriksen PS, Rasmussen H, Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1992;44(2):137- 44.

  97. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics and Gynecology 2001; 97(1): 116-20.

  98. Hulley S, Grady O, Bush T, et al. Randomized tri al ol estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA the journal ol the American Medical Association 1998; 280(7) :605-13.

  99. Hendrix SL, Cochrane BB, Nygaard lE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA: the journal ol the American Medical Association 2005; 293(8):935-48.

  100. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benelits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA: the journal of the American Medical Association 2002; 288(3):321-33.

  101. Anderson GL, Limacher M, Assal AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA: the journal of the American Medical Association 2004; 291(14):1701-12.

  102. Goldstein SR, Johnson S, Watts NB, et al. Incidence of urinary incontinence in postmenopausal women treated with raloxilene or estrogen. Menopause 2005; 12(2):160-4.

  103. Steinauer JE, Waetjen LE, Vittinghoff E, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstetrics and Gynecology 2005; 106(5 Part 1):940-5.

  104. Samsioe G, Jansson I, Mellstrom D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-yearold female population. Maturitas 1985; 7(4):335-42.

  106. Toxina botulínica

  108. Grosse J, Kramer G, Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47:653-9.

  109. Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65:37-41.

  110. Rapp DE, Lucioni A, Katz EE, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 2004;63: 1071-5.

  111. Schulte-Baukloh H, Weiss C, Stolze T. et al. Botulinum-A toxin lor treatment of overactive bladder without detrusor overactivity: Urodynamic outcome and patient satisfaction. Urology 2005;66:82-7.

  112. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. American Journal of Obstetrics and Gynecology 2005; 192:1735-40.

  113. Kuo HC: Comparison of the therapeutic effects of suburothelial injection of botulinum A toxin at different doses for refractory detrusor overactivity. J Urol. 2006;175:113(A34 7).

  114. Kuo HC: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity relractory to anticholinergics. Urology. 2005;66:94-8.

  115. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al.: Botulinum toxin type A is a sale and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196-200.

  116. Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, et al.: Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005; 174: 1873-7.

  117. Rajkumar GN, Small DR, Mustala AW, et al. A prospective study to evaluate the salety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU International 2005;96:848-52.

  118. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, doubleblind, placebo controlled, crossover trial. J Urol 2005; 174:1873-7.

  119. Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No. CD005493. DOI: 10.1002/14651858.CD005493.pub2.

  121. Neuromodulación de nervios sacros

  123. http://www.nice.org.uk/nicemedia/pdl/ip/IPG064guidance.

  124. Brazzelli M, Murray A, Fraser C. Efficacy and salety of sacral nerve stimulation for urinary urge incontinence: A systematic review J Urol 2006;175:835-41.

  125. 3 Elkelini M, Hassouna MM. Canadian experience in sacral neuromodulation. Urol Clin North Am. 2005;32:41-9.

  126. Elhilali MM, Khaled SM, Kashiwabara T, Elzayat E, Corcos J Sacral neuromodulation: longterm experience of one center. Urology. 2005;65:1114-7.

  127. Van Kerrebroeck PE, et al. Results of sacral neuromodulation therapy for urinary voiding dyslunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:1844-5.

  128. Brazzelli M, Murray A, Fraser C Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006; 175(3 Pt 1): 835-41 .

  129. Van Voskuilen AC, et al. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol. 2006;49:366-72.

  130. vvww.nice.org.uk/ip082systematicreview Interventional procedure overview of sacral nerve stimulation for urge incontinence, October 2002.




2020     |     www.medigraphic.com